DM-CHOC-PEN is under clinical development by DEKK-TEC and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect DM-CHOC-PEN’s likelihood of approval (LoA) and phase transition for Breast Cancer took place on 11 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their DM-CHOC-PEN Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

DM-CHOC-PEN overview

DM-CHOC-PEN is under development for the treatment of advanced cancer with involvement of central nervous system such as glioblastoma, melanoma, acute lymphoblastic leukemia, non-Hodgkin lymphoma, astrocytoma, breast cancer, non-small cell lung cancer, oligoastrocytoma or other primary malignant neoplasm. It is a small molecule administered by intravenous route. The drug is a carbonate derivative of 4-demethyl-penclomedine (DM-PEN).

DEKK-TEC overview

DEKK-TEC is a drug development company that develops novel drugs and devices for the management of cancer. The company’s product pipeline includes DM-CHOC-PEN, Pyrroles, IFN-y Fusion Proteins, HOOI, IPM, Progesterone, A-007, and hydroperoxy analogs, among others. Its DM-CHOC-PEN is a lead proprietary investigational anticancer agent that has the potential to cross the blood brain barrier and localize in cancer tissue that is in phase II of clinical trials and being developed for the treatment of brain cancer and central nervous system disorders. DEKK-TEC develops new therapies and clinical development candidates for the treatment of pre-cancerous lesions, cancer, and women’s health issues. The company operates through its manufacturing facility. DEKK-TEC is headquartered in New Orleans, Louisiana, the US.

Quick View DM-CHOC-PEN LOA Data

Report Segments
  • Innovator
Drug Name
  • DM-CHOC-PEN
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.